Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chenchen Yu

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Nature Communications|September 11, 2024
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trialBo Zhang, Youyi Fong, Jonathan Fintzi, et al.
Medrxiv : the Preprint Server for Health Sciences|August 17, 2021
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy TrialPeter B Gilbert, David C Montefiori, Adrian McDermott, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 25, 2025
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccineYouyi Fong, Yunda Huang, Ying Huang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
The Lancet. HIV|May 11, 2026
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trialSharana Mahomed, Carmen A Paez, Yunda Huang, et al.
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Science Translational Medicine|April 19, 2023
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trialDavid Benkeser, David C Montefiori, Adrian B McDermott, et al.
Nature Communications|January 17, 2025
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boostBo Zhang, Youyi Fong, Lauren Dang, et al.
Viruses|October 28, 2023
Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 TrialYing Huang, Nima S Hejazi, Bryan Blette, et al.
Nature Communications|November 12, 2024
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trialLindsay N Carpp, Ollivier Hyrien, Youyi Fong, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Nature Communications|September 11, 2024
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trialBo Zhang, Youyi Fong, Jonathan Fintzi, et al.
Medrxiv : the Preprint Server for Health Sciences|August 17, 2021
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy TrialPeter B Gilbert, David C Montefiori, Adrian McDermott, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 25, 2025
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccineYouyi Fong, Yunda Huang, Ying Huang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
The Lancet. HIV|May 11, 2026
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trialSharana Mahomed, Carmen A Paez, Yunda Huang, et al.
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Science Translational Medicine|April 19, 2023
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trialDavid Benkeser, David C Montefiori, Adrian B McDermott, et al.
Nature Communications|January 17, 2025
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boostBo Zhang, Youyi Fong, Lauren Dang, et al.
Viruses|October 28, 2023
Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 TrialYing Huang, Nima S Hejazi, Bryan Blette, et al.
Nature Communications|November 12, 2024
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trialLindsay N Carpp, Ollivier Hyrien, Youyi Fong, et al.
Pageof 8